The effect of valsartan, an angiotensin II receptor antagonist, on portal and systemic hemodynamics and on renal function in liver cirrhosis.

Aim: The aim of the study was to assess the effects of valsartan, a new generation angiotensin II receptor antagonist, on portal and systemic hemodynamics and on renal function in cirrhosis.

Methods: Eighty patients with cirrhosis and portal hypertension were divided in two groups as follows: group I - 40 patients who received valsartan (Diovan) 80 mg /day for 7 days and group II - 40 patients who received placebo. All the patients had hemodynamic, endocrine and renal parameters measured on day 0 and 7.